Answers are grounded in this paper and cite their sources.
This narrative review summarizes the evidence supporting the use of foundational pharmacotherapies (ACEi, beta-blockers, ARBs, aldosterone blockers) for systolic heart failure.
Heart failure is an important cause of morbidity and mortality. Clinical trials over the past 2 decades have revolutionized the care of patients with systolic heart failure, and substantial data support the use of angiotensin-converting enzyme inhibitors, β-blockers, angiotensin-receptor blockers, and aldosterone blockers in the management of this serious condition. This article reviews the evidence on the pharmacologic treatment of heart failure, with a focus on recent clinical trials.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: